Ocugen’s 2027 Data Crossroads: New Leadership, Fresh Capital, and a Binary Bet on Two Trials

The next twelve months will tell whether Ocugen’s pipeline bets pay off — and the company has just reshuffled its deck ahead of the reveal. Two pivotal readouts anchor the biotech’s near-term trajectory: top-line data for OCU400 in retinitis pigmentosa are due in the first quarter of 2027, with results from the OCU410ST trial in […] The post Ocugen’s 2027 Data Crossroads: New Leadership, Fresh…